Discover a new way to find and share stories you'll love… Learn about Reading Desk

Blog Profile / In the Pipeline

Filed Under:Medical / Pharmaceutical
Posts on Regator:1925
Posts / Week:9.2
Archived Since:November 3, 2010

Blog Post Archive

Nivolumab Racks Up Another Success

I'm always happy to highlight impressive clinical data, and this is impressive. Bristol-Myers Squibb's nivolumab (which has been doing very well in clinical trials so far) apparently has very significant effects in refractory squamous cell lung cancer as well. Show More Summary

Down With the Western Blot?

A reader sends along a thought that touches on a lot of the publication scandals that have happened in molecular biology over the years. A very common feature of these is manipulation of Western blots (see that graphic the other dayShow More Summary

Google's Nanoparticle Diagnostic Ideas

Google's "Google X" division, the part that works on odd high-risk high-reward projects, is apparently interested in diagnostic nanoparticles. That Wired article is pretty short on specifics, but the company's Andrew Conrad revealed a few details in a talk yesterday. Show More Summary

Aileron Heads Toward the Clinic

Aileron, the stapled-peptide company, has had its ups and downs over the past few years. They went through the typical cut-back-hard phase not too long ago, but have been rounding up more money to try out their p53-targeted idea (blogged on here). I'm glad to hear it. Show More Summary

Viehbacher Out at Sanofi

The talk of Chris Viehbacher being in trouble with Sanofi's board of directors was accurate: he's been dismissed. It was a unanimous vote, and the chairman cited a lack of trust and a "solitary management style" as factors. (This after...Show More Summary

Rumblings About AstraZeneca and Antibiotics

Well, let's get the rest of today's bad news out there. There are persistent reports that AstraZeneca is going to be getting rid of the rest of its antibiotics research. David Shlaes' blog is the source of this one, and he may well have some information from people who know. Show More Summary

Amgen Cuts Harder

Not good news. Amgen has announced that it's not just cutting 12 to 15% of its employees - it's going to cut 20% of them. So that means over a thousand new layoffs, on top of the ones that have already been put in the hopper. No details...Show More Summary

An Open-Source Cancer Pitch, Deconstructed

I'm confused. Read this and see if you end up the same way. TechCrunch has the story of Isaac Yonemoto, who's crowdsourcing a project around a potential oncology compound. It's a derivative of sibiromycin, a compound I hadn't come across, but it seems that it was first studied in Russia, and then at Maryland. Show More Summary

Fazlul Sarkar Subpoenas PubPeer

Last month I mentioned that a professor at Wayne State, Fazlul Sarkar, was thinking of suing the PubPeer site or its commenters, after a host of negative comments on his papers disrupted his move to the University of Mississippi. Well,...Show More Summary

Sanofi - Trouble At the Top?

There are reports that Sanofi's CEO, Chris Viehbacher, is in trouble with the company's board of directors. The reasons are various, ranging from his move to Boston, through the state of the company's oncology portfolio, all the way to his outspokenness, which is not very French. Show More Summary

Sarepta's Duchenne Therapy Is A Lot Further Away

I wrote here about Sarepta, a small company having plenty of difficulty getting a therapy for Duchenne muscular dystrophy through the FDA. At that point, the problem was the accelerated-approval pathway, but things have now gotten aShow More Summary

Farzul Sarkar Subpoenas PubPeer

Last month I mentioned that a professor at Wayne State, Fazlul Sarkar, was thinking of suing the PubPeer site or its commenters, after a host of negative comments on his papers disrupted his move to the University of Mississippi. Well,...Show More Summary

Francis Collins Knows Why We Don't Have An Ebola Vaccine

NIH Director Francis Collins has been saying that if only the agency's budget hadn't been cut, that we would already have an Ebola vaccine. He tried this line out during recent Congressional testimony, and apparently liked it enough that he expanded on it in an article for the Huffington Post. Show More Summary

Not The Sort Of Thing You'd Work With, Given a Choice

Here's a paper that illustrates a different way of looking at the world than many medicinal chemists would have. It discusses inhibitors of SETD8, an unusual epigenetic enzyme that is the only known methyltransferase to target lysine 20 of histone H4. Show More Summary

Atmospheric Conditions

Well, I've been busy sciencing away all morning, and we're having the kind of weather outside that makes a person want to stay indoors and do chemistry: rainy, chilly, and windy. You wonder why more big chemical discoveries don't come...Show More Summary

Green Coffee Beans Will Mostly Slim Your Wallet

Very few readers of this site are likely to have a good opinion of Dr. Oz (I certainly don't). And very few readers will be surprised to hear that one of his highly-touted miracle weight loss regiments - green coffee bean extract (GCA) - has turned out to be a load of faked-up nonsense. Show More Summary

Roche Rebuilds

Roche has announced ambitious plans for new buildings at its home base in Basel: They're building a new home for John Reed and Roche's pRED research group in Basel – and the pharma giant is thinking big. Roche said today that it is committing...Show More Summary

Improving the Old-Fashioned Reaction Workup

Here's something new: working up a reaction. The authors say that they have a porous polymer that adsorbs organic compounds from aqueous reaction mixtures, allowing you to just stir and filter rather than doing a liquid/liquid extraction. Show More Summary

Phenylalanine Crystals

No matter how long you've been doing chemistry, there are still things that you come across that surprise you. Did you know that plain old L-phenylalanine has been one of the most difficult subjects ever for small-molecule crystallography? I sure didn't. Show More Summary

Oxygenated Nanobubbles. For Real?

A longtime reader sent along this article, just based on the headline. "This headline triggers instant skepticism in me", he said, and I agree. "Potential to treat Alzheimer's" is both a bold and a weaselly statement to make. The weasel...Show More Summary

Copyright © 2011 Regator, LLC